This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485–1492.
Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666–1672.
Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo–Chiba Hepatitis Research Group. Gastroenterology 1997; 113: 558–566.
Nakamuta M, Fukutomi T, Shimohashi N, Kinukawa N, Uchimura K, Tada S et al. Kinetics of the hepatitis C virus during interferon therapy as a marker of therapeutic response. J Gastroenterol Hepatol 2001; 16: 29–33.
Bressler BL, Guindi M, Tomlinson G, Heathcote J . High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639–644.
Yee LJ, Tang J, Gibson AW, Kimberly R, Van Leeuwen DJ, Kaslow RA . Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001; 33: 708–712.
Knapp S, Yee LJ, Frodsham AJ, Hennig BJ, Hellier S, Zhang L et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun 2003; 4: 411–419.
Hijikata M, Ohta Y, Mishiro S . Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt −88) correlated with the response of hepatitis C patients to interferon. Intervirology 2000; 43: 124–127.
Hijikata M, Mishiro S, Miyamoto C, Furuichi Y, Hashimoto M, Ohta Y . Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: revisited by analyzing two SNP sites (−123 and −88) in vivo and in vitro. Intervirology 2001; 44: 379–382.
Antonelli G, Simeoni E, Turriziani O, Tesoro R, Redaelli A, Roffi L et al. Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy. J Interferon Cytokine Res 1999; 19: 243–251.
Thio CL, Thomas DL, Carrington M . Chronic viral hepatitis and the human genome. Hepatology 2000; 31: 819–827.
Alric L, Izopet J, Fort M, Vinel JP, Fontenelle P, Orfila C et al. Study of the association between major histocompatibility complex class II genes and the response to interferon alpha in patients with chronic hepatitis C infection. Hum Immunol 1999; 60: 516–523.
Sugimoto Y, Kuzushita N, Takehara T, Kanto T, Tatsumi T, Miyagi T et al. A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C. J Viral Hepat 2002; 9: 377–384.
Dorak MT, Folayan GO, Niwas S, Yee LJ, Tang J, van Leevan DJ et al. C-C chemokine receptor 2 (CCR2) and CCR5 genotypes in patients treated for hepatitis C virus infection. Immunol Res 2002; 26: 167–175.
Yee LJ, Perez KA, Tang J, van Leeuwen DJ, Kaslow RA . Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. J Infect Dis 2003; 187: 1264–1271.
Dupuis S, Jouanguy E, Al-Hajjar S, Fieschi C, Al-Mohsen IZ, Al-Jumaah S et al. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet 2003; 33: 388–391.
Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uze G . The type I interferon receptor: structure, function, and evolution of a family business. J Interferon Cytokine Res 1999; 19: 1069–1098.
Author information
Authors and Affiliations
Corresponding author
Additional information
DUALITY OF INTEREST
None declared.
Rights and permissions
About this article
Cite this article
Tang, J., Kaslow, R. Pharmacogenomic perspectives of chronic hepatitis C virus (HCV) infection. Pharmacogenomics J 4, 171–174 (2004). https://doi.org/10.1038/sj.tpj.6500246
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.tpj.6500246